Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/7/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. John Didsbury

Wrong Dr. John Didsbury?

Founder and Chief Executive Offic...

Phone: (919) ***-****  
Email: d***@***.com
T3D Therapeutics Inc
68 T.W. Alexander Drive
Research Triangle Park , North Carolina 27709
United States

Company Description: T3D Therapeutics Inc. is a privately-held Research Triangle Park, NC-based company incorporated in 2013. The company is committed to developing disease remedial...   more

Employment History

Board Memberships and Affiliations


  • Ph.D.
  • PhD
  • Ph.D. , Medical Microbiology
    University of Vermont Medical College
  • Bachelor of Arts , biology/chemistry
    University of Connecticut
92 Total References
Web References
Executive Management Team | T3D Therapeutics, 26 Mar 2015 [cached]
John Didsbury, Ph.D. President & CEO, Chairman of the Board Dr. Didsbury is a seasoned Executive Manager with over 24 years of experience within the pharmaceutical and biotechnology industries in both small and large public and private companies. Dr. Didsbury was President/COO/CSO of DARA BioSciences, Inc. (NASDAQ:CM - DARA). At DARA he led the development of T3D-959 and directed all operations of the business, overseeing all finances, financing efforts, business development, human resources and administration and directing all drug discovery programs of the company in a CSO role. He played a key role in taking the company public in 2008 through a reverse merger. Dr. Didsbury served as CEO of Nuada Pharmaceuticals Inc. Prior to his tenure at Nuada Dr. Didsbury was Head of Strategy and Operations at GlaxoSmithKline, Inc. Previously, Dr. Didsbury served as Associate Director of Biology at Macronex, Inc., as Assistant Professor of Medicine at Duke University Medical Center and as a scientist at Genentech, Inc. Industry news, 18 Feb 2013 [cached]
RALEIGH, North Carolina, March 25 /PRNewswire/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of John Didsbury, Ph.D. as President and Chief Operating Officer. Dr....
Press Releases :: DARA BioSciences, Inc. (DARA), 18 June 2013 [cached]
he T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comprised of leading experts in the field of PPAR science and are extremely familiar with the compound. e believe they will apply the necessary resources to explore DB959 in multiple, potential high-value indications.Importantly, the agreement affords DARA upfront considerations as well as future potential revenue based on progression of the DB959 developmental program."
DARA previously reported that it was actively seeking to out-license DB959 as part of its strategic plan to focus on the commercialization of oncology supportive care products.
John Didsbury, Ph.D., Founder and Chief Executive Officer of T3D Therapeutics, commented, "The T3D Therapeutics team has a long history with DB959, and we plan to develop it as a transformational new therapy for the treatment of Alzheimer's disease.Unlike other therapies in development that target a single pathology, typically the reduction or prevention of beta amyloid plaque buildup, T3D expects DB959 will afford a multidimensional opportunity, with the potential to improve several Alzheimer's disease pathologies including addressing beta amyloid plaque issues.Positive improvements in disease pathologies such as neuro-inflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles, and insulin resistance / lowered cerebral glucose metabolism also are anticipated."
Didsbury continued, "With today's highly competitive diabetes and dyslipidemia market, we believe that DB959 will be better positioned to address unmet medical needs for new central nervous system (CNS) therapies.Given the neuroprotectant potential of DB959's mechanism of action and the growing evidence of metabolic disorders contributing to CNS diseases, we are excited to commence an aggressive development program for DB959."
John Didsbury, Ph.D. T3D Therapeutics CEO 919-949-0517
John Didsbury, ..., 5 Feb 2015 [cached]
John Didsbury, Ph.D
President/Chief Executive Officer Nuada Pharmaceuticals Inc.
Dr. Didsbury has over 18 years of executive management experience within pharmaceutical and biotechnology industries. He took three drug discovery programs to selection of clinical candidate molecules within 14 months by raising $10 Million. Dr. Didsbury has been associated the following companies: Nuada Pharmaceuticals (CEO), GlaxoSmithKline, Macronex, Genentech and Duke University Medical Center. He earned his B.A. in Biology/Chemistry at University of Connecticut in 1977, and his Ph.D. in Medical Microbiology at University of Vermont Medical College in 1982.
John Didsbury, Ph.D. (View ..., 19 April 2011 [cached]
John Didsbury, Ph.D. (View Profile) President and CEO, DDCOI
Other People with the name "Didsbury":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.